Australia’s medical research community continues to push the boundaries of innovation, rapidly translating cutting-edge therapies from the lab to clinical trials.
In this exclusive webinar, experts from Griffith University, the Clem Jones Centre and Accelagen will present the process and results of their groundbreaking collaboration on a world-first clinical trial for spinal cord injury treatment. Learn how their novel cell therapy technology is advancing with the support of Australia’s world-class regulatory framework and research infrastructure. Discover how a leading Australian clinical research organization (CRO) is playing a crucial role in accelerating this transformative therapy from discovery to human trials—offering new hope for patients worldwide.
Spinal cord injuries have long been among the most challenging medical conditions to treat, often resulting in permanent disability. In this webinar, the expert speakers will focus on a Phase I clinical trial that explores the use of olfactory ensheathing cells (OECs)—specialised cells from the nose known for their nerve repair properties. By harvesting and reintroducing these cells into the injury site, researchers aim to bridge damaged nerve tissues, stimulate regeneration and restore lost functions such as mobility and sensation.
Register for this webinar today to understand how a pioneering clinical trial in spinal cord injury treatment led by top Australian researchers.
Speakers
Greg Plunkett, CEO and Managing Director, Accelagen
Greg Plunkett is the CEO and Managing Director of Accelagen, founding the company in 2010. He is an innovative, values-driven and forward-thinking senior regulatory affairs professional. Greg has over 20 years of experience in product development, quality and management. Driving excellence, innovation and ingenuity, he is a passionate advocate for healthcare accessibility and bringing the best technologies and innovation to the masses.
Message Presenter
Dr. James St John, PhD, Head of the Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University
Prof James St John is Head of the Clem Jones Centre for Neurobiology and Stem Cell Research. Prof. James is a translational neuroscientist specialising in the creation and delivery of therapies to repair injuries and diseases of the nervous system. He has a particular interest in understanding the biology of the olfactory system (sense of smell) and the therapeutic use of glial cells to repair the nervous system.
The three main areas of research are (1) spinal cord injury, (2) peripheral nerve injury and (3) the role of microbes in neurodegeneration. The major project of the Centre is the translation of a cell transplantation therapy to repair spinal cord injury. This therapy is now progressing to a clinical trial that will commence in late 2024 in Queensland, Australia.
Read more...
Since the commencement of the Centre, Prof St John has been Lead Investigator on more than $35 million of research projects funded by philanthropy, state and federal government including NHMRC and MRFF funding. Prof St John obtained his PhD in 1996 in Agricultural Science from the University of Melbourne. He then applied his expertise in carbohydrate synthesis and manipulation to determining the role of carbohydrates in the development and regeneration of the mammalian brain.
He held positions as an NHMRC post-doctoral fellow at the University of Melbourne and University of Queensland, and has been Chief Investigator of NHMRC and ARC grants at the University of Queensland and Griffith University. In 2007, he took up the position of Group Leader at the Griffith Institute for Drug Discovery at Griffith University and in May 2016 he became Head of the Clem Jones Centre for Neurobiology and Stem Cell Research.
Read Less...
Dr. Andrew Rayfield, Research Fellow and Research Commercialisation Manager for the Clem Jones Centre for Neurobiology and Stem Cell Research (CJCNSCR), Griffith University
Dr. Andrew Rayfield is a Research Fellow and Research Commercialisation Manager for the Clem Jones Centre for Neurobiology and Stem Cell Research (CJCNSCR). Andrew spends his time at the CJCNSCR labs in Brisbane and on the Gold Coast. Andrew is a molecular and cellular neuroscientist by training with six years’ experience in industry and nearly twenty years experience in academia. Andrew’s role as Research Commercialisation Manager for the Centre is to develop and translate the Centre’s three main areas of preclinical research (developing a therapy for spinal cord injury; developing a therapy for peripheral nerve injury and identifying the causes of and developing diagnostics for neurodegeneration) into clinical products.
Read more...
Andrew previously helped run the GUSIP01 and the GUSIP02 feasibility clinical trials where Griffith was the sponsor. The aim of these trials were to test the feasibility of an intensive exercise-based rehabilitation for spinal cord injury patients. In addition to management roles in the Centre, Andrew has a keen interest in the cellular biology of glia, has developed skills in qualitative research to help assess the barriers and facilitators of intensive exercise rehabilitation for spinal cord injury patients and has an interest in implementation science.
Andrew’s main focus, however, is in research commercialisation and entrepreneurship. Since 2020, Andrew has been a member of the Griffith Pride Committee and commenced as Co-Chair in 2022 and as Chair in 2024. Andrew believes it is important to be true to yourself in all aspects of your life, including bringing your true self to the workplace. Something a lot of people in the world still cannot or are unable to do.
Read Less...
Who Should Attend?
This is a must-attend event for researchers, healthcare professionals, SCI patients, advocacy groups and anyone interested in the latest breakthroughs in spinal cord injury treatment.
What You Will Learn
Attendees will learn about:
- The years of discovery research leading to a world-first clinical trial for spinal cord injury treatment
- The unique challenges and strategies involved in bringing this novel therapy to patients
- How this innovative study is being conducted and the regulatory, ethical and logistical considerations in running a world-first cell therapy trial
- How this research could revolutionise not just SCI treatment but also other neurodegenerative conditions
Xtalks Partner
Accelagen
Accelagen is a leading, globally adept Contract Research Organisation (CRO) headquartered in Melbourne, Australia. With a combined 160+ years of delivered success, the Accelagen team’s experience varies widely across the health, wellness and disease spectrum. Additionally, we offer end-to-end services across Strategic Consultation, Clinical Trials, Regulatory Affairs, Biometrics and Medical, Safety & Pharmacovigilance. Accelagen provides customised, flexible, agile and cost-effective clinical solutions to help big pharma and emerging biotech companies get their innovative treatments to patients and to market quickly. The Accelagen team adopts a collaborative approach to partnering with clients across the globe to make a tangible difference to the future of human health and wellness.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account